Charged Particle Radiotherapy

Description of Procedure or Service

Charged-particle beams consisting of protons or helium ions or carbon ions are a type of particulate radiation therapy (RT). They contrast with conventional electromagnetic (i.e., photon) radiation therapy due to several unique properties including minimal scatter as particulate beams pass through tissue, and deposition of ionizing energy at precise depths (i.e., the Bragg peak). Thus, radiation exposure of surrounding normal tissues is minimized. The theoretical advantages of protons and other charged-particle beams may improve outcomes when the following conditions apply:

- Conventional treatment modalities do not provide adequate local tumor control;
- Evidence shows that local tumor response depends on the dose of radiation delivered; and
- Delivery of adequate radiation doses to the tumor is limited by the proximity of vital radiosensitive tissues or structures.

The use of proton or helium ion radiation therapy has been investigated in two general categories of tumors/abnormalities. However, advances in photon-based radiation therapy (RT) such as 3-D conformal RT, intensity-modulated RT (IMRT), and stereotactic body radiotherapy (SBRT) allow improved targeting of conventional therapy.

1. Tumors located near vital structures, such as intracranial lesions or lesions along the axial skeleton, such that complete surgical excision or adequate doses of conventional radiation therapy are impossible. These tumors/lesions include uveal melanomas, chordomas, and chondrosarcomas at the base of the skull and along the axial skeleton.
2. Tumors at risk of local recurrence despite maximal doses of conventional radiation therapy.

Proton beam therapy can be given with or without stereotactic techniques. Stereotactic approaches are frequently used for uveal tract and skull-based tumors. For stereotactic techniques, 3 to 5 fixed beams of protons or helium ions are typically used.

Related Policies:
Epiretinal Radiation Therapy for Age-Related Macular Degeneration

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.

Policy

BCBSNC will provide coverage for Charged Particle Radiotherapy (Proton or Helium Ion) when it is determined to be medically necessary because the medical criteria and guidelines shown below are met.

Benefits Application
Charged Particle Radiotherapy

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When Charged Particle Radiotherapy is covered

Charged particle irradiation with proton or helium ion beams may be considered medically necessary for the following clinical indications:

1) Primary therapy for melanoma of the uveal tract (iris, choroid or ciliary body), with no evidence of metastasis or extrascleral extension, and with tumors up to 24 millimeters in largest diameter and 14 millimeters in height.

2) Post-operative therapy (with or without conventional high energy X-rays) in patients who have undergone biopsy or a partial resection of chordoma or low grade (I or II) chondrosarcoma of the basi-phenoid region (skull-base chordoma or chondrosarcoma) or cervical spine. Patients eligible for this treatment have residual localized tumor without evidence of metastasis.

3) Solid tumors in the pediatric population being treated with curative intent.

When Charged Particle Radiotherapy is not covered

Charged particle irradiation is considered investigational for all other indications not addressed above under, “When Charged Particle Radiotherapy” is covered, including but not limited to, use of proton beam therapy for:

- clinically localized prostate cancer;
- non-small-cell lung cancer (NSCLC) at any stage or for recurrence;
- tumors of the head and neck, (other than skull-based chordoma or chondrosarcoma).

Policy Guidelines

For individuals who have uveal melanoma(s) who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes RCTs and systematic reviews. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. Systematic reviews, including a 1996 TEC Assessment and a 2013 review of randomized and non-randomized studies, concluded that the technology is at least as effective as alternative therapies for treating uveal melanomas and is better at preserving vision. The evidence is sufficient to determine qualitatively that the technology results in a meaningful improvement in the net health outcome.

For individuals who have skull-based tumor(s) (ie, cervical chordoma and chondrosarcoma) who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes observational studies and systematic reviews. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. A 2016 systematic review of observational studies found 5-year survival rates after proton beam therapy ranging from 67% to 94%. The evidence is sufficient to determine qualitatively that the technology results in a meaningful improvement in the net health outcome.

For individuals who have pediatric solid tumors who receive charged-particle radiotherapy, the evidence is limited to dosimetric planning studies, small case series and a few non-randomized comparative studies. Relevant outcomes are overall survival, disease-free survival, change in disease status and treatment-related morbidity. Larger studies with longer-term follow up are needed to establish efficacy of charged particle compared with other conformal radiation treatments (eg IMRT) in the pediatric population. However, due to the particular vulnerability of children to the toxicity of
Charged Particle Radiotherapy

radiation, the benefits of charged-particles likely outweigh the risk of long-term side effects and secondary malignancy induction compared with other radiation modalities.

For individuals who have localized prostate cancer who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes 2 RCTs and systematic reviews. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. A 2010 TEC Assessment addressed the use of PBT for prostate cancer and concluded that it has not yet been established whether PBT improves outcomes in any setting for clinically localized prostate cancer. The TEC Assessment included 2 RCTs, only 1 of which included a comparison group of patients who did not receive proton-beam therapy. No data on the use of PBT for prostate cancer have been published since 2010 that would alter the conclusions of the TEC Assessment. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have non-small-cell lung cancer who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes case series and systematic reviews. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. A 2010 TEC Assessment included 8 case series and concluded that the evidence is insufficient to permit conclusions about proton beam therapy for any stage of non-small cell lung cancer. No subsequent randomized or non-randomized comparative studies have been published. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have head and neck tumors other than skull-based who receive charged-particle (proton or helium ion) radiotherapy, the evidence includes case series and a systematic review. Relevant outcomes are overall survival, disease-free survival, change in disease status, and treatment-related morbidity. The evidence is insufficient to determine the effects of the technology on health outcomes. The systematic review noted that the studies no charged-particle therapy were heterogenous in terms of type of particle and delivery techniques, and that there are no head to head trials comparing charged-particle therapy to other treatments. The evidence is insufficient to determine the effects of the technology on health outcomes.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable service codes: 77520, 77522, 77523, 77525, S8030

Charged Particle Radiotherapy typically consists of a series of CPT codes describing the individual steps used. CPT codes 77520, 77522, 77523, and 77525 may be used for treatment delivery of proton beam therapy.

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources

National Association TEC Review - 1/96

Charged Particle Radiotherapy

Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Proton Beam Therapy for Non-Small-Cell Lung Cancer. 2010
Medical Director review 7/2015
Sr. Medical Director review 7/2016
Specialty Matched Consultant Advisory Panel 5/2017
Charged Particle Radiotherapy

Specialty Matched Consultant Advisory Panel 5/2018
Medical Director review 5/2018

Specialty Matched Consultant Advisory Panel 5/2020
Medical Director review 5/2020

Specialty Matched Consultant Advisory Panel 5/2021
Medical Director review 5/2021

Medical Director review 10/2021

Specialty Matched Consultant Advisory Panel 5/2022
Medical Director review 5/2022
Specialty Matched Consultant Advisory Panel 5/2023
Medical Director review 5/2023

Policy Implementation/Update Information

For Policy titled “Charged Particle Radiotherapy (Proton or Helium Ion)

3/96 Local policy issued.
3/99 Reaffirm
6/99 Reformatted, Definition of Procedure or Service revised, Medical Term Definitions added.
12/00 77520, 77522, 77523, and 77525 added to coding section. System coding changes.
11/01 Coding format change.
1/04 Benefits Application and Billing/Coding sections updated for consistency.
4/10/06 Specialty Matched Consultant Advisory Panel review 3/15/2006. Added additional indications to "When covered" section to include; "B. Charged particle radiotherapy may be considered medically necessary for treatment of arteriovenous malformations (AVM) or
Charged Particle Radiotherapy

acoustic neuromas that meet the following criteria: the lesion is unresectable and the lesion is too large (>3cm) and irregularly shaped to be treated with standard radiotherapy. C. Charged particle radiotherapy may be considered medically necessary for treatment of pituitary adenomas and nasopharyngeal carcinoma that is recurrent after standard radiation therapy. Rationale added to "Policy Guidelines" section. References added.

8/28/06 Medical Policy changed to Evidence Based Guideline.

6/02/08 Specialty Matched Consultant Advisory Panel review 3/17/08. Added additional indication to "When covered section: “D. Charged particle radiotherapy may be appropriate using standard treatment doses in patients with clinically localized prostate cancer.” Removed this indication from the “When not covered” section. References added. (btw)

6/22/10 Specialty Matched Consultant Advisory Panel review 5/24/2010. Updated “Description section”. Added additional indication to “When not covered section: C. “In patients with clinically localized prostate cancer, because the clinical outcomes with this treatment have not been shown to be superior to other approaches including intensity modulated radiation therapy (IMRT) or conformal radiation therapy, yet proton beam therapy is generally more costly than these alternatives.” Removed this indication from the “When covered section.” References added. (lpr)

11/9/10 Evidenced Based Guideline changed to Medical Policy. Under When Covered section: removed B “Charged particle radiotherapy may be appropriate for treatment of arteriovenous malformations (AVM) or acoustic neuromas that meet the following criteria—lesion is unresectable and lesion is too large (>3cm) and irregularly shaped to be treated with standard radiotherapy; also removed C. Charged particle radiotherapy may be appropriate for treatment of recurrent pituitary adenomas and nasopharyngeal carcinoma following standard radiation therapy. Under When Not Covered section: removed A. For indications other than those listed above, B. For melanoma outside the eye, chondrosarcoma, or chordoma at sites other than the skull base or spine.” Under When Not Covered” section: added including but not limited to use of proton beam therapy for non-small-cell lung cancer (NSCLC) at any stage or for recurrence. Rationale updated in “Policy Guidelines” section. References added. “Notification given 11/9/10. Effective date 2/15/11. Reviewed with Senior Medical Director. (lpr)


7/29/14 Specialty Matched Consultant Advisory Panel review meeting 6/24/2014. No change to policy statement. Reference added. (lpr)

7/1/15 Specialty Matched Consultant Advisory Panel review 5/27/2015. Reference added. No change to policy statement. (lpr)

9/1/15 Under “When Covered” section: charged particle radiotherapy for clinically localized prostate cancer changed from not medically necessary to investigational. Senior medical director review 7/2015. Reference added. (lpr)

For Policy titled “Charged Particle Radiotherapy”
Charged Particle Radiotherapy


6/30/17 Specialty Matched Consultant Advisory Panel review 5/31/2017. No change to policy statement. (lpr)

8/25/17 Reference added. No change to policy statement. (lpr)


5/28/19 Specialty Matched Consultant Advisory Panel review 5/15/2019. No change to policy intent. Reference added. (lpr)

6/9/20 Specialty Matched Consultant Advisory Panel review 5/20/2020. No change to policy statement. (lpr)

6/15/21 Specialty Matched Consultant Advisory Panel review 5/19/2021. No change to policy statement. Reference added. (lpr)

11/2/21 Under “When Covered” section: added statement 3) Solid tumors in the pediatric population being treated with curative intent. Updated policy guidelines, reference added. Medical Director review 10/2021. (lpr)

5/31/22 Specialty Matched Consultant Advisory Panel review 5/18/2022. No change to policy statement. (lpr)

6/30/23 Specialty Matched Consultant Advisory Panel review 5/17/2023. No change to policy statement. (lpr)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.